학술논문
A randomized, placebo-controlled, blind anti-AIDS clinical trial: safety and immunogenicity of a specific anti-IFN-alpha immunization
Document Type
Periodical
Author
Gringeri, A.; Santagostino, E.; Mannucci, P.M.; Tradati, F.; Cultraro, D.; Buzzi, A.; Criscuolo, M.; David, A.; Guillemot, L.; Barre-Sinoussi, F.; Lachgar, A.; Chams, V.; Le Coq, H.; Fouchard, M.; Achour, A.; Fall, L.; Defer, M.C.; Picard, O.; Hermans, P.; Burny, A.; Feldman, M.; Chany, C.; Zagury, J-F.; Bizzini, B.; Zagury, D.
Source
Journal of Acquired Immune Deficiency Syndromes. Sept 1994, Vol. 7 Issue 9, p978, 11 p.
Subject
Language
ISSN
0894-9255
Abstract
Injections of inactivated interferon-alpha (i-IFN-alpha) may reduce the overproduction of this immune system protein in HIV-infected patients. Overproduction of IFN-alpha occurs early in the infection and may contribute to the severe immunosuppression that occurs. Twenty-two HIV-infected people were injected at monthly intervals with various preparations of i-IFN-alpha. Twenty patients in the control group received placebos. The most common side effects were soreness at the injection site and fever. T cell counts increased in all the patients receiving i-IFN-alpha but declined in the control group. At the end of the nine-month study, no measurable IFN-alpha was found in blood samples of those treated, including the six who had measurable levels at the start of the study. None of those treated with the compound had to begin AZT treatment, but four taking the placebo did.